Automate and standardize your regulatory management, from correspondence and commitments to registration and tracking.
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn moreDeveloping IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MOREReimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewGenerate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWElevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWOrchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWWhen your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSBy making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MOREBuilding on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MOREYour new expert analyst is here. Be at the forefront of data-driven decision-making with a new generative AI tool that enables you to interact with our products and solutions like never before. Get results you can trust, faster.
LEARN MOREThe IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MOREThe IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MOREIQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MOREEmpowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MORE"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.
VIEW ROLESMedicines New Zealand (MNZ), the professional trade association representing the Pharmaceutical industry in the country, in collaboration with the New Zealand Medical Association, which represents New Zealand Healthcare Professionals (HCPs), announced new Transfer of Value (ToV) transparency reporting guidelines developed by a joint working group comprising members of both organizations.
The directive encompasses a range of ToVs such as event registration fees and expenses, along with fees paid for consultative and other services. These new transparency reporting obligations became effective in New Zealand as of January 1, 2021, and the first disclosure deadline is set for June 30, 2022. Companies that implement proactive compliance strategies will be at a competitive advantage.
The working group published details of its Joint Transparency Initiative on the Medicines New Zealand website (https://www.medicinesnz.co.nz/transparency-guidelines/) on December 22, 2020. They said the new guidelines are intended as a voluntary framework for defining, enumerating and reporting financial as well as in-kind support provided to HCPs in the context of furthering their medical knowledge through activities like educational speaker programming. The guidelines also align with the Medicines New Zealand Code provisions that pertain to HCP interactions and relationships.
The joint group said in an FAQ on the Medicines New Zealand website that the intention is that this disclosure guidance will facilitate “increasing trust and confidence” among the general public that interactions involving ToVs between doctors and drug-makers “both support patient care and increase medical knowledge.”
The new Joint Transparency Initiative guidelines stipulate that pharmaceutical companies — members of MNZ — are obligated to disclose both payments as well as in-kind transfers made to HCPs and Healthcare Organizations (HCOs). The new protocols apply to payments to HCPs in exchange for services such as hosting a presentation or serving as a consultant; expenses incurred in the course of providing these services such as airline tickets, lodging and meals; professional and educational event registration fees, along with any associated expenses incurred in the course of attending those functions.
Industry stakeholders should take note: There is no minimum threshold for ToV reporting requirements. No matter how minimal, each and every payment and ToV must be accounted for and reported. Additionally, disclosure and reporting is required for ToVs made directly by manufacturers as well as those conferred by intermediaries.
The scope of professionals and organizations to whom these requirements apply is broad, including: medical, dental, nursing and pharmaceutical professionals, professionals outside these categories who provide prescription medicine advice or access, as well as HCOs, including hospitals and medical practices.
The initial reporting period began on January 1, 2021, and the first reporting deadline is fast approaching: June 30, 2022, at which time all ToVs made during calendar year 2021 must be disclosed via reports — which must be publicly available — on member companies’ websites. In subsequent years, reporting will continue on a calendar year basis, and disclosure reporting will be due 6 months after each reporting period has concluded. Documentation must be accessible online for at least three years following publication. While the disclosure guidelines are voluntary, member companies are encouraged to comply with these rules as part of their own risk mitigation strategies.
For the Life Sciences industry, this is significant. While collaboration between HCPs and manufacturers is a key component to advancing both medical knowledge and improved patient health outcomes, the regulatory and organizational framework in which this partnership takes place has undergone dynamic changes.
In recent years, more countries and regions have begun adopting Sunshine Law-type regulatory regimes around transparency disclosure and reporting. It is incumbent on manufacturers to adopt policies and protocols — and invest in the necessary technological infrastructure — that allow them to proactively adapt to these kinds of changes.
Automate and standardize your regulatory management, from correspondence and commitments to registration and tracking.
Meet the challenge of changing stakeholder demands and increasing cost constraints with IQVIA's integrated technology services and analytics-driven offerings.